Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI-D: CHF 5993 DPI vs pMDI in COPD
NCT03590379Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Started Jun 2018; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03590379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590379.